Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab
Pre-treatment epigenetic age acceleration appears to be a novel biomarker for cardiotoxicity risk that improves cardiotoxicity risk prediction.
Authors
- Mohammed Al‐Jumayli (ORCID: https://orcid.org/0000-0002-5164-9163)
- Rachel de Sá Barreto Luna Callou Cruz (ORCID: https://orcid.org/0000-0002-4596-313X)
- Anders Berglund (ORCID: https://orcid.org/0000-0002-0393-3530)
- Jamila Mammadova (ORCID: https://orcid.org/0009-0008-2163-0788)
- Christine Sam (ORCID: https://orcid.org/0000-0002-8593-2936)
- Jacob K. Kresovich (ORCID: https://orcid.org/0000-0002-9577-226X)
- Jong Y. Park (ORCID: https://orcid.org/0000-0002-6384-6447)
- Dae Hyun Lee (ORCID: https://orcid.org/0000-0001-8141-0404)
- Alicia Richards
- Evan Adler
- Mohammed Alomar (ORCID: https://orcid.org/0000-0002-4713-7245)
- S. Palfi
- Adriana Gonzalez-Torriente
Institutions
- University of South Florida (US)
- Jacksonville College (US)
- Moffitt Cancer Center (US)
- Jackson Health System (US)
- Mayo Clinic in Florida (US)
- University of Virginia (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1186/s40959-025-00340-7
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Moffitt Cancer Center
- National Cancer Institute